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Introduction: Acute coronary syndromes and non-Q-wave myocardial infarction are often 
initiated by platelet activation. Eptifibatide is a cyclic heptapeptide and is the third inhibi-
tor of glycoprotein (Gp) IIb/IIIa that has found broad acceptance after the specific antibody 
abciximab and the nonpeptide tirofiban entered the global market. Gp IIb/IIIa inhibitors act 
by inhibiting the final common pathway of platelet aggregation, and play an important role 
in the management of acute coronary syndromes.
Aims: This review assesses the evidence for therapeutic value of eptifibatide as a Gp IIb/IIIa 
inhibitor in patients with acute coronary syndromes.
Evidence review: Several large, randomized controlled trials show that eptifibatide as adjunc-
tive therapy to standard care in patients with non-ST segment elevation acute coronary syndrome 
is associated with a significant reduction in the incidence of death or myocardial infarction. Data 
are limited regarding the use of eptifibatide in patients with ST segment elevation myocardial 
infarction. Cost-effectiveness analysis indicates that eptifibatide is associated with a favorable 
cost-effectiveness ratio relative to standard care. According to US cost-effectiveness analysis 
about 70% of the acquisition costs of eptifibatide are offset by the reduced medical resource 
consumption during the first year. Eptifibatide was well tolerated in most of the trials. Bleeding 
is the most commonly reported adverse event, with most major bleeding episodes occurring at 
the vascular access site. Major intracranial bleeds, stroke, or profound thrombocytopenia rarely 
occurred during eptifibatide treatment.
Place in therapy: Eptifibatide has gained widespread acceptance as an adjunct to standard 
anticoagulation therapy in patients with acute coronary syndromes, and may be particularly 
useful in the management of patients with elevated troponin or undergoing percutaneous coro-
nary interventions.
Keywords: eptifibatide, integrilin, myocardial infarction, unstable angina, acute coronary 
syndrome, percutaneous coronary intervention
Core evidence place in therapy summary for eptifibatide in the management of 
acute coronary syndrome
Outcome measure Evidence Implication
Patient-oriented evidence
improvement in 
cardiovascular morbidity 
and mortality
Clear Lower risk with 
eptifibatide compared 
with placebo
Incidence of MI Clear Lower risk with 
eptifibatide compared  
with placebo
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Scope, aims, and objectives
Eptifibatide (Integrilin®, Millennium, Schering-Plough 
Corporation) is a cyclic heptapeptide and is the third inhibitor 
of glycoprotein (Gp) IIb/IIIa that has found broad acceptance 
as a potent inhibitor of the Gp IIb/IIIa platelet receptor. This 
review summarizes the development, rationale, and use of 
this agent in the management of patients with acute coronary 
syndromes (ACS).
Methods
English language literature searches were conducted on 
June 5–10, 2007 in the following databases to date unless 
otherwise stated. The search strategy was “(myocardial 
infarction OR unstable angina OR acute coronary syndrome)” 
AND “(eptifibatide OR integrilin).
•  Ovid MEDLINE® 1950 to present with daily update. The 
following limits were applied: English language and “all 
adult (19 plus years)” and “clinical trial, all or controlled 
clinical trial or guideline or meta analysis or multicenter 
study or practice guideline or randomized controlled trial or 
review.”
•  A combined database including Cochrane DSR (Database 
of Systematic Review), ACP (American College of 
Physicians) Journal Club, DARE (Database of Abstracts 
of Reviews of Effects), and CCTR (Cochrane Central 
Register of Controlled Trials).
•  Ovid MEDLINE inprocess and other nonindexed cita-
tions June 4, 2007.
Online abstracts from the following congresses were searched 
using the search strategy “eptifibatide” unless otherwise stated:
•  European Society of Cardiology Congress (ESC) 2006/
World Congress of Cardiology (WCC) 2006, ESC Congress 
2005 http://www.escardio.org/knowledge/congresses/
abstracts/.
(Continued)
Outcome measure Evidence Implication
improvement in quality 
of life
None
Disease-oriented 
evidence
Urgent target vessel 
revascularization
Moderate Lower incidence com-
pared with placebo
Incidence of hemorrhage Clear increased incidence 
of major and minor 
bleeding with add-on 
eptifibatide compared 
with standard therapy 
alone
Incidence of  
thrombocytopenia
Limited Slightly increased risk 
of thrombocytopenia 
with add-on eptifibatide 
compared with standard 
therapy alone
Incidence of stroke Limited Increased risk of 
hemorrhagic stroke 
with add-on eptifibatide 
compared with standard 
therapy alone
Economic evidence
Cost effectiveness  
compared with other 
glycoprotein
Clear More cost-effective than 
abciximab in NSTE ACS
iib/iiia inhibitor
Cost effectiveness in ACS Clear Favorable for eptifibatide 
as an adjunct to standard 
care relative to standard 
care alone
Abbreviations:   ACS, acute coronary syndrome; MI, myocardial infarction; NSTE ACS, non-ST segment elevation   ACS.Core Evidence 2009:4 51
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After removal of duplicates, a total of 160 records 
were identified. Records were manually reviewed and 
59 studies were excluded because the studies were in 
other diseases or the articles were not investigating the 
clinical use of eptifibatide in acute coronary syndrome 
(Table 1).
Disease overview
ACS has evolved as a useful operational term to refer to any 
constellation of symptoms that are compatible with acute 
myocardial ischemia. It encompasses myocardial infarc-
tion (MI) (ST segment elevation and depression, Q wave, 
and non-Q wave) and unstable angina (UA). Disruption of 
plaques is now considered to be the common pathophysi-
ologic substrate of an ACS. When plaque disruption occurs, 
a sufficient quantity of thrombogenic substances is exposed 
(eg, tissue factor), and the coronary artery lumen may become 
obstructed by a combination of platelet aggregates, fibrin, 
and red blood cells.
Mural, nonocclusive, white thrombi, consisting 
predominantly of aggregated platelets, are the cause of 
cardiac ischemia in most patients (90%) with UA.1,2 The 
pathophysiologic characteristics of non-Q wave MI are 
similar to those of UA, but this syndrome is accompanied 
by more severe ischemia and evidence of myocardial 
necrosis.3,4 White thrombi also represent an initial stage in 
the formation of arterial, occlusive red thrombi that produce 
complete blockage of a coronary artery in acute Q-wave 
(ST elevation) MI.
The arterial red thrombus is composed of red blood cells 
enmeshed within a fibrin network. However, it is built on 
a white thrombus core that creates regions of blood stasis 
conducive stated: to fibrin deposition and provides platelet 
the coagulation cascade.3–5
The realization that uncontrolled platelet aggregation 
could be responsible for thrombosis was appreciated as long 
ago as 1881, and the concept that thrombosis is the primary 
cause of ACS has been universally accepted in the last two 
decades.4,5 Thus, efforts to prevent ACS have logically 
focused on development of therapeutic interventions that 
block platelet aggregation, or coagulation, or both.
Platelet activation occurs through distinct and sometimes 
redundant physiologic pathways.4 The ultimate result of 
the action of these activation signals is platelet aggrega-
tion, mediated by cation dependent attachment of divalent 
fibrinogen molecules to activated platelets. This cross link-
ing of platelets through fibrinogen bridges constitutes the 
final common pathway in the platelet-mediated thrombus 
formation. Studies on Glanzmann’s thrombasthenia, a rare, 
inherited, recessive bleeding disorder, provided the first 
evidence that the integrin Gp IIb/IIIa is the receptor for this 
crucial fibrinogen-binding event.6
The Gp IIb/IIIa complex is the most abundant receptor 
on the platelet surface. The heterodimeric, ligand-binding 
Gp IIb/IIIa complexes are not normally exposed in their 
active forms on the surfaces of the quiescent circulating 
platelets. However, platelet activation converts Gp IIb/IIIa 
into competent receptors by means of specific signal trans-
duction pathways,7 enabling Gp IIb/IIIa to bind fibrinogen 
and von Willebrand’s factor. When two activated platelets 
with functional Gp IIb/IIIa receptors each bind the same 
fibrinogen molecule, a fibrinogen bridge is created between 
the two platelets. Because the surface of each platelet has 
about 50 000 Gp IIb/IIIa fibrinogen binding sites, numerous 
activated platelets recruited to the site of vascular injury can 
rapidly form an occlusive aggregate by means of a dense 
network of intercellular fibrinogen bridges.8 This Gp IIb/
IIIa-mediated platelet aggregation has served as a target for 
antiplatelet therapy with Gp IIb/IIIa antagonists.9
Disease burden
ACS are a major cause of emergency medical care and 
hospitalization in the US. In 2004, the National Center for 
Health Statistics reported 1 565 000 hospitalizations for 
primary or secondary diagnosis of an ACS, 669 000 for UA, 
and 896 000 for MI.
According to the British Heart Foundation (BHF), around 
230 000 people in the UK suffer a heart attack each year and 
in around 30% of heart attacks, the patient dies. Coronary 
Table 1 Evidence base included in the review
Category Number of records
  Full papers Abstracts
initial search 155 5
  records excluded 59 0
  records included 96 5
Level 1 clinical evidence 3 0
Level 2 clinical evidence 39
Level 3 clinical evidence 27
Level 4 clinical evidence 9
Level 5 clinical evidence 6
Economic evidence 10
Case reports 2
Notes: For definitions of levels of evidence, see Core Evidence website (http://www.
dovepress.com/core-evidence-journal).Core Evidence 2009:4 52
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heart disease is the most common cause of premature death 
in the UK, causing 105 000 deaths a year.10
Current therapy options
Antiplatelet therapy is the mainstay of therapy in the 
treatment of patients with ACS that are managed medically or 
those undergoing percutaneous coronary intervention (PCI) 
given the importance of platelet activation and aggregation 
in thrombus formation. Aspirin has been the foundation 
of antiplatelet therapy and it is recommended as standard 
therapy in patients with non-ST segment elevation ACS 
(NSTE ACS) with or without PCI as a result of its efficacy 
and low cost.11,12 Aspirin is an inhibitor of thromboxane 
A2-induced platelet aggregation and lacks potency and 
specificity.13 Lately, aspirin “resistance” has been reported 
in some patients with cardiovascular disease, with coronary 
events occurring despite daily aspirin treatment.14 Thieno-
pyridines (clopidogrel and ticlopidine) are the other class of 
antiplatelet agents that act through a different mechanism. 
They inhibit binding of adenosine diphosphate (ADP) to its 
platelet receptor thereby inhibiting the subsequent ADP-
mediated activation of the Gp IIb/IIIa complex, and thus 
inhibiting platelet aggregation.12 Clopidogrel reduces the 
incidence of recurrent ischemic events in patients with ACS 
and after coronary stenting. However, resistance to clopido-
grel has also been reported.15
Antithrombotic agents are another class of drugs used in 
patients with ACS. Unfractionated heparin and low molecular 
weight heparin (LMWH) are also used in the treatment of 
patients with non-ST segment elevation ACS and/or those 
undergoing PCI.
These agents exert their anticoagulant effect by 
accelerating the rate at which circulating antithrombin 
(a proteolytic enzyme) inactivates coagulation factors IIa 
(thrombin), IX, and Xa.11 Bivalirudin is a peptide that 
directly inhibits the activity of thrombin and has been used 
as a substitute for heparin.11 However, these agents are not 
antiplatelet agents, but exert their anticoagulant effect on 
thrombin.
The most groundbreaking development in antiplatelet 
therapy in recent years has been the development of the 
intravenous GP IIb/IIIa receptor antagonists (eptifibatide, 
abciximab [ReoPro® Centocor, Eli Lilly], tirofiban 
[Aggrastat®, Merck Co Inc]).
Antiplatelet and anticoagulation therapies are essential 
for the prevention of thromboembolic-induced myocardial 
ischemia in non-ST elevation ACS and the ischemic 
complications of PCI. Heparin, direct thrombin inhibitors, 
and oral platelet activation inhibitors all provide substantial 
benefit, but as Gp IIb/IIIa inhibitors block the final common 
pathway leading to platelet aggregation, the American College 
of Cardiology/American Heart Association (ACC/AHA) 
guidelines recommend Gp IIb/IIIa inhibitors as an integral 
component of care in these patients. The treatment guidelines 
for the use of GP IIb/IIIa antagonist in UA/ non-ST segment 
elevation myocardial ischemia (NSTEMI) are shown in 
Table 2.
Despite the ACC/AHA recommendations, the NRMI-4 
(National Registry of Myocardial Infarction 4) and CRU-
SADE (Can rapid Risk stratification of Unstable angina 
patients Suppress ADverse outcomes with early implemen-
tation of the ACC/AHA guidelines?) registries observed 
Table 2 American College of Cardiology/American Heart Associa-
tion guidelines for use of Gp IIb/IIIa antagonists in the management 
of unstable angina pectoris/non-ST segment elevation myocardial 
infarction11
Class ia A Gp iib/iiia antagonist should be administered, in
addition to Asp and heparin, to patients in whom
catheterization and PCi are planned
The Gp IIb/IIIa antagonist may also be administered just
prior to PCib
Class iiac Eptifibatide or tirofiban should be administered, in 
addition to Asp and LMwH or UFH, to patients with
continuing ischemia, elevated troponin levels, or with
other high-risk features in whom invasive management
is not plannedb
A Gp iib/iiia antagonist should be administered to
patients already receiving heparin, Asp, and clopidogrel
in whom catheterization and PCi are planned
The Gp IIb/IIIb antagonist may also be administered just
prior to PCid
Class iibc Eptifibatide or tirofiban should be administered, in
addition to Asp and LMwH or UFH, to patients without
continuing ischemia who have no other high-risk
features and in whom PCI is not plannedb
Class iiie Abciximab administration in patients in whom PCi is
not plannedb
Notes: aConditions for which there is evidence and/or general agreement that a given 
procedure or treatment is useful and effective.
bEvidence from multiple, large, randomized clinical trials.
cConditions for which there is conflicting evidence and/or divergence of opinion 
about the usefulness/efficacy of a procedure or treatment: IIa=weight of evidence 
is in favor of usefulness/efficacy; IIb=usefulness/efficacy is less well established by 
evidence/opinion.
dEvidence from a limited number of small randomized trials or from careful analysis 
of nonrandomized studies or observational registries.
eCondition for which there is evidence and/or general agreement that the procedure/
treatment is not useful/effective and in some cases may be harmful.
Abbreviations: Asp, aspirin; Gp, glycoprotein; LMwH, low molecular weight heparin; 
PCI, percutaneous coronary intervention; UFH, unfractionated heparin.Core Evidence 2009:4 53
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that only 25%–32% of eligible patients received early 
Gp IIb/IIIa therapy, despite a 6.3% absolute mortality reduc-
tion in NRMI-416 and a 2% absolute mortality reduction in 
CRUSADE.17
Comparison of Gp IIb/IIIa inhibitors
The three available Gp IIb/IIIa inhibitors are abciximab, 
tirofiban, and eptifibatide. Potentially important differences 
exist between these agents.
Abciximab, a human-murine chimeric Fab fragment of 
a monoclonal antibody against the Gp IIb/IIIa receptor, was 
the first agent of this class to demonstrate clinical effective-
ness. The molecular weight of abciximab is 47 615 daltons.
Eptifibatide is a synthetic cyclic heptapeptide with a molecu-
lar weight of 800 daltons, whereas tirofiban is a nonpeptide 
with a molecular weight of 495 daltons.
It takes about 4 hours to restoration of normal platelet 
aggregation after end of infusion of eptifibatide or tirofiban. 
Abciximab, on the other hand, binds much more avidly 
to the Gp IIb/IIIa receptor than the other two agents and 
has a measurable antiplatelet activity for several days 
(72 hours).18
An increased incidence of thrombocytopenia was also 
observed as a result of treatment with abciximab,19 including 
an increase in severe thrombocytopenia (in 0.7% of patients 
receiving primary treatment, and in 2.2% with retreatment), 
which suggests that some caution should remain with any 
readministration of abciximab.
All three agents are available for use in UA/NSTEMI, 
with abciximab currently approved only in patients 
undergoing PCI.
Eptifibatide in combination  
with other medications
The antiplatelet activity of eptifibatide was the same when 
coadministered with either unfractionated heparin or the 
LMWH enoxaparin sodium in ex-vivo studies in healthy 
volunteers.20 No difference was found in the antiplatelet 
activity in patients with ACS undergoing coronary angiog-
raphy when eptifibatide was used either with enoxaparin or 
unfractionated heparin.21 The inhibition of thrombus forma-
tion was significantly greater when eptifibatide was coad-
ministered with enoxaparin sodium than with unfractionated 
heparin [reduction of 75.6% versus 63.9% (P = 0.01)].
Bivalirudin, a direct thrombin inhibitor, can also be used 
concomitantly with eptifibatide in patients undergoing PCI.22 
An ex-vivo study in patients undergoing PCI showed that 
during the important periprocedural period (first 8 hours), the 
inhibition of platelet aggregation with unfractionated heparin 
or bivalirudin alone was 80%.23 Notably, the inhibition of 
platelet aggregation was significantly (P  0.01) greater with 
combination therapy (eptifibatide plus unfractionated heparin 
or bivalirudin) than with either unfractionated heparin or 
bivalirudin alone at all time points during the infusion.
The addition of eptifibatide therapy in patients with 
non-ST segment elevation ACS undergoing PCI or elective 
stenting achieved provides significant with clopidogrel and 
aspirin alone.24,25 Inhibition of platelet aggregation was 
increased at least two-fold when eptifibatide (double bolus 
dose of 180 mcg/kg then infusion of 2.0 mcg/kg/min) was 
added to a regimen of clopidogrel 600 mg in the 24 hours after 
patients were stented.25 In addition, the release of markers of 
myocardial necrosis (creatinine kinase MB, troponin I, myo-
globin) after PCI was significantly lower when eptifibatide 
was combined with clopidogrel (P  0.05). Conformation-
ally activated Gp IIb/ IIIa receptor expression after platelet 
activation with ADP was reduced by 48% with clopidogrel 
300 mg plus aspirin therapy, with a further reduction of 80% 
occurring in patients receiving additional eptifibatide (bolus 
dose of 180 mcg/kg and then an infusion of 2.0 mcg/kg/min) 
(both P  0.0001 versus baseline).24
The use of Gp IIb/IIIa in combination with fibrinolytics 
has potentially several beneficial effects. The combination 
would attack both the red and the white components of the 
occlusive thrombus, improve reperfusion and microvascu-
lar flow, and might reduce the incidence of postfibrinolytic 
hemorrhagic stroke if lower dosages of fibrinolytics are used 
in the combination regimens. Several trials assessing the 
use of eptifibatide in combination with either full-dose or 
half-dose fibrinolytics have shown significant improvement 
in the achievement of thrombolysis in myocardial infarction 
(TIMI) grade lll flow.26,27 ST segment recovery has also been 
shown to be more stable and faster with eptifibatide plus a 
thrombolytic agent.28
Unmet needs
Although eptifibatide and the other two Gp IIb/IIIa inhibitors, 
by acting on the final common pathway to platelet aggrega-
tion, represent an important strategy, there are some potential 
disadvantages. Attempts to develop new drugs in this class 
to overcome these disadvantages are ongoing.
Oral Gp iib/iiia inhibition
Because of the benefits of intravenous Gp IIb/IIIa inhibitors, 
it was hypothesized that prolonged Gp IIb/IIIa inhibi-
tion using oral agents might further improve outcomes. Core Evidence 2009:4 54
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Unfortunately, multiple large trials have failed to show any 
benefit of this approach.29,30 In addition, a 35% increase in 
mortality was seen across the trials.
Hemorrhage and thrombocytopenia
In a meta analysis of the large placebo-controlled trials, major 
bleeding was shown to have occurred in 2.4% of patients 
treated with Gp IIb/IIIa inhibitors versus 1.4% for placebo 
(P  0.0001).31
Thrombocytopenia is an uncommon but important 
complication of Gp IIb/IIIa inhibitors. For tirofiban 
in PRISM-PLUS, the rate of severe thrombocytopenia 
(50 000 cells/mm3) was 0.5% versus 0.3% for heparin. In 
the PURSUIT trial, thrombocytopenia (20 000 cells/mm3) 
occurred in 0.2% compared with 0.1% for heparin. 
Thrombocytopenia is associated with increased bleeding 
and, in a smaller proportion of patients, recurrent thrombotic 
events.32 This syndrome bears resemblance to heparin-
induced thrombocytopenia and indicates a need to monitor 
platelet count daily during Gp IIb/IIIa infusion.
Pharmacology of eptifibatide
Eptifibatide is a peptide derived from a protein found in 
the venom of the southeastern pygmy rattlesnake Sistrurus 
miliarus barbouri.33,34 It is a cyclic heptapeptide, containing 
six amino acids and a mercaptopropionyl residue. It belongs 
to the so called arginine-glycine-aspartate-mimetics and 
reversibly binds to platelets. It has a modified lysine-
glycine-aspartate (KGD) amino acid sequence within its 
structure, which is similar to the physiologic arginine-
glycine-aspartate (RGD) sequence of adhesive ligands, such 
as von Willebrand’s factor and fibronectin, which bind to 
platelet Gp IIb/IIIa receptors.
In contrast to abciximab, eptifibatide is highly specific for 
the Gp IIb/IIIa receptor, with a relatively low binding affinity. 
Since eptifibatide rapidly dissociates from its receptor, 
normal platelet aggregation is restored approximately 4 hours 
after discontinuation of an infusion.34 Eptifibatide is not 
immunogenic and is safe for repeated administration.35
Dosing regimens
Eptifibatide inhibits platelet aggregation in a dose-dependent 
manner, as demonstrated by ex-vivo studies.36–38 However 
variability has been seen in inhibition of platelet aggregation 
using different ex-vivo techniques, which has been attributed 
to the anticoagulant [sodium citrate or PPACK (D-phenylala-
nyl-l-prolyl-l-arginine chloromethyl ketone)] or the agonist 
[ADP, thrombin receptor agonist peptide (TRAP)] used.36,38,39 
When anticoagulants are used that chelate calcium, the 
affinity of Gp IIb/IIIa for fibrinogenis reduced and the inhibi-
tory effect of the antagonist is overestimated.40 On the other 
hand, if TRAP is used as the platelet agonist this might under-
estimate the in-vivo effects of eptifibatide; TRAP causes more 
platelet degranulation and surface Gp IIb/IIIa expression than 
ADP, and increases the ability of platelets to aggregate.38,39 
The dosing regimens used in the IMPACT II trial (Integrilin 
to Minimize Platelet Aggregation and Coronary Thrombosis) 
were 135 mcg/kg bolus followed by 0.5 mcg/kg/min infusion 
for 20–24 hours, or 135 mcg/kg bolus plus 0.75 mcg/kg/min 
infusion for 20–24 hours. Plasma concentrations of eptifi-
batide during infusion were at the levels expected to inhibit 
ADP-stimulated platelet aggregation in citrate anticoagulated 
blood by 70% to 100%. However, as previously discussed, 
the use of citrate for anticoagulation in platelet aggregation 
assays leads to a decrease in ionized calcium concentration 
and the in-vivo antiplatelet effects of eptifibatide are therefore 
overestimated. In PPACK-anticoagulated blood, which is 
more representative of in-vivo physiologic conditions, the 
degree of inhibition of ADP-induced platelet aggregation by 
the infusion doses of eptifibatide used in IMPACT II trial 
would be significantly lower (35%–50%).41
Because of the findings of the IMPACT II trial, as well 
as the realization of caveats inherent in performing platelet 
aggregation assays in blood anticoagulated with citrate, the 
specific dosing regimen chosen for the PURSUIT (Platelet 
Gp IIb/IIIa in Unstable Angina: Receptor Suppression Using 
Integrilin Therapy) trial was based on an ex-vivo platelet 
aggregation assay that used PPACK as the anticoagulant. 
The dosing regimen for eptifibatide used in the PURSUIT 
trial was a bolus of 180 mcg/kg followed by 2.0 mcg/kg/min 
infusion.42,43 With this dosing regimen, inhibition of platelet 
aggregation was 84% at 15 min after the bolus dose and 
exceeded 90% at steady state. Within 1 hour of the initial 
eptifibatide bolus, there was a slight loss of inhibition, sug-
gesting a multicompartmental model of distribution of this 
agent.36,38 Since PCI is often performed within this timeframe, 
the ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa 
Receptor with Integrilin Therapy) trial adopted a regimen that 
included a second bolus dose (administered within affinity. 
10 min of the first) to ensure adequate inhibition of platelet 
aggregation during PCI.44
We have reported a novel dosing regimen for eptifibatide in 
patients undergoing elective PCI. We used a single high-dose 
20 mg (full vial) bolus of eptifibatide, and observed the level of 
platelet inhibition to be equivalent to the inhibition reported by 
the TEAM investigators after two weight-adjusted boluses.45 Core Evidence 2009:4 55
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The clinical outcomes in this high-dose, single-vial bolus 
protocol appeared to be at least equivalent to the outcomes 
observed in the ESPRIT trial, using weight-adjusted bolus 
plus infusion of eptifibatide in elective stenting.
Clinical evidence with eptifibatide
Non-ST segment elevation  
acute Mi (Table 3)
More than 30 000 patients have been enrolled in large, 
randomized clinical trials comparing inhibition of the platelet 
Gp IIb/IIIa receptor with standard therapy in patients under-
going percutaneous coronary revascularization and those 
with ACS who do not have ST segment elevation.46 Although 
the magnitude of benefit has varied, there has consistently 
been a reduction in the incidence of death and myocardial 
infarction and the need for revascularization.
In the PURSUIT trial43 a total of 10 948 patients were 
enrolled. This landmark multicenter trial found that eptifiba-
tide reduced the incidence of death or nonfatal MI at 30 days. 
The absolute 1.5% reduction was achieved early during 
the drug infusion and persisted through 30 days. Coronary 
intervention was performed at the discretion of the treating 
physician and thus not subject to randomization. The use of 
eptifibatide was associated with increased bleeding and a 
more frequent need for transfusions compared with placebo. 
Although we observed a beneficial effect of eptifibatide in 
men, the results were less clear in women. The benefit of 
eptifibatide was evident at 96 hours and the maintenance of 
this benefit without attenuation persisted up to 30 days.
The INTERACT trial47 randomized 746 patients to evalu-
ate the efficacy of enoxaparin versus unfractionated heparin 
in high-risk patients with non-ST segment elevation ACS 
receiving eptifibatide and aspirin. At 30 days, there was a 
44% relative reduction in death or MI in the enoxaparin-
treated group (5% versus 9%, P = 0.031). Limitations of the 
study include the fact that it was an open-label study and that 
the time to coronary revascularization was 101 hours.
The 9 500-patient EARLY ACS trial,48 which was due to 
complete in July 2008, evaluates the utility of early eptifiba-
tide administered as a double bolus plus infusion compared 
with initial placebo therapy with provisional eptifibatide 
begun just before PCI in patients with non-ST segment 
elevation ACS in whom an invasive approach is planned no 
sooner than the next calendar day. This study will also pro-
vide important information regarding the interaction between 
biomarkers, genetics, prognosis, and the magnitude of benefit 
from early use of eptifibatide in patients with non-ST segment 
elevation ACS.
In summary, in the large landmark PURSUIT trial, the 
moderate absolute reduction of 1.5% in the incidence of death 
or nonfatal MI was achieved with eptifibatide in a real-life 
setting and in a broad population of patients. PURSUIT 
represents the largest study of Gp IIb/IIIa inhibition to date, 
and is consistent with the overall reduction of death and MI 
observed with this class of drugs. Among high-risk patients 
with non-ST segment evaluation ACS, treatment with the 
LMWH enoxaparin in combination with eptifibatide was 
associated with a lower rate of major bleeding at 96 hours, 
as well as lower rates of ischemia during and immediately 
following treatment and lower rates of death or MI at 
30 days.
ST segment elevation Mi (Table 4)
Studies have investigated the use of eptifibatide as combina-
tion therapy with fibrinolytics or prior to primary PCI in the 
emergency room.
Reperfusion in the infarct-related artery is a main predic-
tor of survival after thrombolysis for acute MI.36 Accelerated 
alteplase restores normal perfusion but only in approximately 
50% of cases,27,49 perhaps even less at the tissue level.26 
Only modest success has come from pharmacologic and 
other approaches to improving the incidence and speed of 
reperfusion.
The IMPACT-AMI Investigators36 demonstrated in a 
small randomized, placebo-controlled, dose-ranging trial that 
the incidence and speed of reperfusion can be enhanced when 
a potent Gp IIb/IIIa inhibitor is combined with accelerated 
alteplase, aspirin, and intravenous heparin. One hundred and 
thirty-two patients in a 2:1 ratio received a bolus and con-
tinuous infusion of one of six eptifibatide doses or placebo. 
Another 48 patients were randomized in a 3:1 double-blind 
fashion to receive the highest eptifibatide dose from the first 
phase or placebo. All patients received accelerated alteplase, 
aspirin, and intravenous heparin infusion; all but two groups 
also received an intravenous heparin bolus. The highest 
eptifibatide dose group from the nonrandomized phase and 
the randomized patients were pooled for analysis and com-
pared with placebo-treated patients. The primary endpoint 
was TIMI grade lll flow at 90-min angiography. Secondary 
endpoints were time to ST segment recovery, an inhospital 
composite endpoint (death, reinfarction, stroke, revascular-
ization procedures, new heart failure, or pulmonary edema), 
and bleeding variables.
The groups receiving the largest dose of eptifibatide had 
more complete reperfusion (TIMI grade lll flow, 66% versus 
39% for placebo-treated patients; P = 0.006) and a shorter Core Evidence 2009:4 56
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median time to ST segment recovery (65 versus 116 min 
for placebo; P = 0.05). The groups had similar rates of the 
composite endpoint (43% with eptifibatide versus 42% with 
placebo) and severe bleeding (4% versus 5%). However, 
the patients enrolled in the trial were relatively low risk. 
Elderly patients and those with cardiogenic shock were 
excluded, which may have resulted in some selection bias. 
Secondly, this was a small study of 180 patients, of whom 
only 51 received the largest dose of eptifibatide. Thus, 
interpretations should be made with caution.
In the INTRO-AMI trial26 patients were enrolled in a 
dose-finding (phase a, n = 344) followed by a dose-confirmation 
(phase b, n = 305) protocol. All patients received aspirin and 
weight-adjusted heparin and underwent angiography at 60 and 
90 min. In phase a, eptifibatide in a single or double bolus 
(30 min apart) of 180, 180/90, or 180/180 mcg/kg followed 
by an infusion of 1.33 or 2.0 mcg/kg min was sequentially 
added to alteplase 25 or 50 mg. In phase b, patients were ran-
domized to: double-bolus eptifibatide 180/90 mcg/kg (30 min 
apart) and 1.33 mg/kg/min infusion, with alteplase 50 mg 
(group I); 180/90 mcg/kg (10 min apart) and 2.0 mg/kg/min, 
with alteplase 50 mg (group II); or full-dose, weight-adjusted 
alteplase (group III).
In phase a, the best rate of TIMI flow grade lll was 
achieved using 180/90/1.33 mcg/kg per min eptifibatide 
with 50 mg alteplase: 65% and 78% at 60 and 90 min, 
respectively.
In phase b, the incidence of TIMI flow grade III at 
60 min was 42%, 56%, and 40%, for groups I through III, 
respectively (P = 0.04, group II versus group III). The 
median corrected TIMI frame count was 38, 33, and 50, 
respectively (P = 0.02). TIMI major bleeding was reported 
in 8%, 11%, and 6%, respectively; intracranial hemorrhage 
occurred in 1%, 3%, and 2% of patients (P  0.5 for both). 
The incidences of death (4%, 5%, and 7%), reinfarction, or 
revascularization at 30 days were similar among the three 
treatment groups.
This study showed that double-bolus (within a 10-min 
interval) and high-dose infusion of eptifibatide combined 
with half-dose alteplase is superior to standard-dose alteplase 
alone in achieving reperfusion of the infarct-related artery 
60 min after initiation of therapy. A 16% absolute difference 
in TIMI flow grade III was achieved without a significant 
bleeding events, although a higher nominal rate of intracranial 
hemorrhage was observed in the patients with the highest 
rate of reperfusion. More than 75% of the episodes of major 
bleeding were associated with the catheterization access site 
and did not affect clinical outcome. Like any intervention, 
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the clinical utility of this strategy hinges on the trade off 
between safety and efficacy.
In the INTEGRITI trial,27 combination reperfusion 
therapy with eptifibatide and reduced dose tenecteplase 
for ST segment elevation MI (STEMI) TIMI grade III 
flow rates were similar across groups (64%–68%). Arterial 
patency was highest for a regimen of eptifibatide 180 mcg/kg 
bolus followed by 2.0 mcg/kg/min infusion, then a second 
180 mcg/kg bolus 10 min later plus half-dose tenecteplase 
(eptifibatide 180/2/180 plus half-dose tenecteplase; 96% 
versus 84% with eptifibatide 180/2/90 plus half-dose 
tenecteplase; P = 0.02). In dose confirmation, the combina-
tion of eptifibatide 180/2/180 plus half-dose tenecteplase 
compared with tenecteplase monotherapy tended to achieve 
TIMI grade lll flow in slightly more patients (59% versus 
49%; P = 0.15), slightly greater arterial patency (85% 
versus 77%; P = 0.17), and ST segment resolution slightly 
more frequently (median 71% versus 61%; P = 0.08) but 
was associated with a somewhat greater incidence of major 
hemorrhage (7.6% versus 2.5%; P = 0.14) and requirement 
for transfusions (13.4% versus 4.2%; P = 0.02). Intracranial 
hemorrhage occurred in 1.0%, 0.6%, and 1.7% of patients 
treated with any combination, eptifibatide 180/2/180 and 
half-dose tenectaplase, and tenecteplase monotherapy, 
respectively. This randomized controlled, open-label, phase 
II angiographic trial therefore tended to suggest that double-
bolus eptifibatide 180/2/180 plus half-dose tenecteplase may 
improve angiographic flow and ST segment resolution com-
pared with tenecteplase monotherapy but may be associated 
with more transfusions and noncerebral bleeding.
In another trial50 the effect of emergency room administra-
tion of eptifibatide before primary angioplasty for STEMI on 
baseline coronary flow and procedure outcomes was assessed. 
The results of this study show that for patients undergoing 
primary angioplasty for STEMI, administering eptifibatide 
early after presentation and before arrival in the cardiac cath-
eterization laboratory provides partial reperfusion and may 
decrease procedure complexity. Of 30 patients who received 
eptifibatide administered as a double bolus of 180 mcg/kg 
with the initial bolus given 51 ± 27 min before baseline 
angiography, 17 (56.7%) had TIMI grade ll or lll flow. In 
addition, the time from baseline angiography to first balloon 
inflation was less for these patients, including those who did 
not achieve partial reperfusion. This advantage was offset 
by a delay in the time from emergency room presentation 
to baseline angiography, such that time from presentation 
to balloon inflation was similar in the two groups. The total 
procedure time and length of stent required for those lesions 
in which stents were implanted were significantly less for 
patients who received early eptifibatide treatment. Although 
in a relatively small number of patients, these findings sug-
gest that in addition to improved flow characteristics, early 
administration of eptifibatide may modify the thrombotic 
lesion, facilitating the performance of angioplasty.
The INTAMI study51 was a small randomized trial that 
assigned 102 patients with STEMI  12 hours to primary 
percutaneous intervention with early eptifibatide given in 
the emergency room or optional eptifibatide at the time of 
PCI (late or no). The primary endpoint was the patency of 
the infarct vessel before PCI. Patients in the early group 
received their first eptifibatide bolus a mean of 45 min 
before angiography. TIMI grade III patency before PCI was 
observed in 34% in the early group and 10% in late or no 
group (P = 0.01). The incidence of complete ST resolution 
1 hour after PCI was similar at 61% in the early group and 
66% in the late or no group. Furthermore, there were no 
significant differences in the rates of TIMI grade III flow 
after PCI, death, reinfarction, stroke, and major bleeding 
complications until day 30. However, the trial was not 
powered to detect differences in clinical endpoints.
TITAN-TIMI 3452 was a randomized, phase IV, 
open-label, multicenter trial to evaluate the angiographic and 
clinical efficacy of early initiation of eptifibatide in patients 
intended to undergo primary PCI for acute STEMI. Patients 
were randomized 1:1 in blocks of 10 at each study site to 
receive eptifibatide (180/2/180) to be started either imme-
diately in the emergency department (ED) or other triage 
unit (early ED administration) (n = 174) versus initiation 
in the cardiac catheterization laboratory (CCL) (n = 142) 
after diagnostic catheterization (late CCL administration). 
The primary endpoint of corrected TIMI frame count on 
diagnostic angiography was lower (ie, faster) in the ED 
group (77.5 frames versus 84.3 frames; P = 0.049). TIMI 
grade ll or lll flow was higher in the ED group (46.2% versus 
36.6%; P = 0.087), while the rate of TIMI grade lll flow 
was 24.0% in the ED group and 19.0% in the CCL group 
(P = 0.29). TIMI myocardial perfusion grade lll was pres-
ent more frequently in the ED group (24.3% versus 14.2%; 
P = 0.026). There was no difference in post-PCI TIMI frame 
count (20 versus 22 frames; P = 0.14), TIMI flow grade (87% 
versus 89%; P = not significant), or TIMI myocardial perfu-
sion grade (37% versus 37%; P = not significant). However, 
full angiographic perfusion score (APS), which integrates 
pre-PCI and post-PCI epicardial and myocardial perfusion, 
trended better in the ED group (APS of 10–12, 21.1% versus 
12.5%; P = 0.059).Core Evidence 2009:4 59
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Hence a strategy of early initiation of eptifibatide in the 
ED before primary PCI for STEMI yields superior pre-PCI 
TIMI frame counts, reflecting epicardial flow and superior 
TIMI myocardial perfusion compared with a strategy of 
initiating eptifibatide in the CCL.
In summary, there are limited trials using eptifibatide in 
early invasive strategy of management of STEMI. Most of 
the early trials used abciximab and tirofiban. The available 
data at best suggest a superior TIMI flow grade as well as 
perfusion grade with the use of eptifibatide at the cost of 
increased hemorrhagic complications.
Economic evidence
In the PRICE study53 a prospective economic analysis showed 
that median total inhospital costs (1999/2000 year of costing) 
were significantly lower in eptifibatide than in abciximab 
recipients ($US7207 versus $US8268 per patient; P = 0.009). 
The between-group difference in cost was largely attributable 
to the higher acquisition costs within the abciximab-treated 
group. Inhospital charges, 30-day total costs, and 30-day 
total charges were also significantly (P  0.01) lower with 
eptifibatide than abciximab.
Retrospective analyses54–56 that compared eptifibatide 
with abciximab as adjunctive therapy in patients undergoing 
PCI have generally indicated that eptifibatide was associated 
with lower acquisition costs and similar or lower total medi-
cal costs or charges per patient; clinical outcomes were simi-
lar with the two agents. These studies varied in methodologies 
and year of costing, but were all conducted in the US; several 
of these studies also included tirofiban as a comparator. In the 
largest of these studies (data from 32,529 patients reviewed), 
the incremental cost-effectiveness ratios of eptifibatide, 
abciximab, and tirofiban compared with standard treatment 
were $US21,731, $US14,515, and $US163,286 per life-year 
gained, respectively (year of costing 2000/2001).
Several cost-effectiveness analyses used prospectively 
collected data from the PURSUIT trial and modeled survival 
projections using similar methods. These analyses, conducted 
in the US, Canada, and Western Europe, also showed favor-
able results ($US3761–$US18 774 per life-year gained; 
various years of costing).57 Cost-utility ratios reported in 
US analyses varied somewhat, but remained $US20 000 
per quality-adjusted life-year gained (1996 values) when 
clinical efficacy data were derived from the US cohort of 
PURSUIT.
Significant clinical benefits have been demonstrated 
with eptifibatide as adjunctive therapy in patients undergo-
ing selective PCI with stent implantation in the ESPRIT 
trial and in patients with ACS in the PURSUIT trial. 
Pharmacoeconomic analyses using data from these trials have 
demonstrated favorable cost-effectiveness ratios for both 
indications in various countries.57 ESPRIT-based results from 
the limited number of available economic analyses are par-
ticularly favorable.57 In US economic analyses using ESPRIT 
trial data, approximately 40% and 70% of the acquisition 
cost of eptifibatide was offset by reduced medical resource 
consumption during the initial hospitalization period and 
over a 1-year period, respectively. Eptifibatide was associ-
ated with a favorable cost-effectiveness ratio of $US1407 
(year 2000 values) per life-year gained in a retrospective 
US cost-effectiveness analysis that incorporated datafromthe 
ESPRITtrial and modeled life expectancy using a large car-
diovascular database.
The cost effectiveness of eptifibatide in ACS may be 
further improved by targeting the drug for patients in whom 
catheterization and PCI are planned, although further analy-
ses are required to confirm this.
Resource utilization
In the ESPRIT trial the estimated inhospital costs for each 
patient on the basis of hospital resource consumption 
(procedure duration, number of stents received, length of 
stay), occurrence of adverse outcomes (death, periprocedural 
acute MI, repeat PCI, inhospital coronary artery bypass 
graft surgery, major bleeding complications), and treat-
ment received58 were estimated on the basis of measured 
resource consumption, using a published regression model. 
Costs associated with length of stay and adverse outcomes 
were estimated from a second regression model, which 
was based on measured hospital costs for 3241 patients 
who underwent PCI between 1996 and 1999 at 89 US 
hospitals (model R2 = 0.69). Reflecting the observed reduc-
tions in stent use and procedure duration, initial procedural 
costs were $US151 lower per patient for patients treated with 
eptifibatide compared with placebo. In addition, hospital 
costs related to treatment of periprocedural ischemic com-
plications were $US61 lower per patient for the eptifibatide 
group. However, there were no significant differences in 
costs related to the length of stay or treatment of vascular 
complications. As a result, mean total initial hospital costs 
(excluding eptifibatide) were $US185 lower per patient for 
the eptifibatide group compared with placebo ($US10,226 
versus $US10,412; P = 0.15). When the cost of study drug 
was included, mean total initial hospital costs were increased 
by $US292 per patient with eptifibatide compared with 
placebo ($US10722 versus $US10,430; P  0.001).Core Evidence 2009:4 60
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However, a US cost-effectiveness analysis (year of 
costing 2000) indicated that eptifibatide was associated with 
a favorable cost-effectiveness ratio of $US1407 per life-year 
gained relative to standard care.57 Approximately 70% of the 
acquisition costs of eptifibatide were offset by the reduced 
medical resource consumption during the first year.
Patient group/population
Eptifibatide has been studied in different patient populations. 
The efficacy of low dose eptifibatide was first evaluated in a 
small number of patients (n = 150) in the IMPACT-I trial.59 
The patients in this study were undergoing low-and high-risk 
coronary intervention. The data from the larger IMPACT-II 
trial provided the initial supporting evidence for the effi-
cacy of a low-dose regimen (bolus of 135 mcg/kg then a 
continuous intravenous infusion of 0.5 or 0.75 mcg/kg/min) 
of this agent in this indication.46 There was no significant 
difference between eptifibatide and placebo recipients in the 
incidence of the primary composite endpoint of death, MI, 
or urgent target vessel revascularization (UTVR) at 30 days 
in this trial.
Based on these data and results from other pharmacody-
namic studies, the ESPRIT trial44 investigated the efficacy 
of an eptifibatide dosage that was three- to four-fold higher 
than that used in the IMPACT-II trial. The researchers from 
the ESPRIT trial concluded that as adjunctive treatment in 
patients with low- to moderate-risk coronary artery disease 
undergoing PCI with stent placement, eptifibatide achieved 
significant reductions in ischemic complications and was 
better than a strategy of reserving treatment for the bailout 
situation. The risk of the primary endpoint (a composite of 
death, MI, UTVR, and bailout to open-label eptifibatide 
within 48 hours) was significantly reduced with eptifibatide 
versus placebo [risk ratio (RR) 0.63; 95% confidence interval 
(CI) 0.47, 0.84]. This benefit associated with eptifibatide 
occurred across different subgroups regardless of sex, pres-
ence of diabetes, or other comorbid clinical conditions. In 
addition, eptifibatide recipients had a significantly lower risk 
of secondary endpoint (death, MI, or UTVR at 30 days) (RR 
0.65; 95% CI 0.47, 0.87).
Subsequent follow-up analyses of these trials60,61 indicated 
that adjuvant eptifibatide therapy provides long-term benefit. 
In addition to the lower combined incidence of death, MI, or 
UTVR in eptifibatide than in placebo recipients at 48 hours 
and 30 days, the incidence was also lower with eptifibatide 
at 6 and 12 months.
Eptifibatide has also been studied in various patient popu-
lations with ACS. In the PURSUIT trial 1228 patients were 
enrolled who had NSTEMI and underwent PCI during the 
first 72 hours of the trial.62 The incidence of the composite 
endpoint death or MI within 30 days was significantly lower 
in eptifibatide than in placebo recipients (11.6% versus 
16.7%; P = 0.01). The between-group difference was not 
significant in the other 8233 patients who did not undergo 
early PCI (14.6% versus 15.6%). In another retrospective 
analysis of PURSUIT trial data of patients randomized in 
the US (who received earlier intervention strategies than 
those from other regions) (n = 4035), the reduction in the 
30-day risk of the composite endpoint significantly favored 
eptifibatide versus placebo recipients (P  0.05), both in 
patients who underwent an early PCI and in those who did 
not (relative risk reductions of 33% and 19%).63
Data are limited regarding the use of eptifibatide in 
patients with STEMI. Studies have investigated the use of 
eptifibatide prior to primary PCI in the emergency room50 or 
as combination therapy with fibrinolytics26,27,36,49 in patients 
with STEMI. Eptifibatide is not currently approved in these 
indications.
The early administration of eptifibatide in the emergency 
room before primary PCI in patients with STEMI resulted in 
a significantly higher rate of partial or complete reperfusion 
than standard treatment.49 The effect of combination therapy 
with eptifibatide plus a fibrinolytic on surrogate markers 
of epicardial and myocardial reperfusion in patients with 
STEMI has been examined in phase II clinical trials26,27,36,49 
and a meta analysis.28 The primary endpoint in these trials 
was generally the proportion of patients with TIMI grade lll 
flow assessed by angiography. All patients in these studies 
received aspirin and unfractionated heparin. The phase III 
ADVANCE-MI trial was initiated to evaluate the efficacy 
of eptifibatide alone or in combination with reduced-dose 
tenecteplasein patients with STEMI who were to undergo 
PCI within 4 hours. The primary endpoint of this trial was 
an improvement in patient survival and a reduction in the 
rate of congestive heart failure, but the trial was terminated 
early. In two trials [INTRO-AMI26 and IMPACT-AMI]36 
significantly more patients receiving eptifibatide in combina-
tion with alteplase, compared with those receiving alteplase 
alone, experienced TIMI grade lll flow. However, in the 
INTEGRITI trial,27 adding eptifibatide to tenecteplase or 
streptokinase49 did not significantly improve this outcome. 
The proportion of patients with TIMI grade ll or lll flow was 
also greater with eptifibatide plus a fibrinolytic than with a 
fibrinolytic alone in two trials. However, in the latter trial49 
the addition of eptifibatide to full-dose streptokinase was 
associated with an increase in bleeding.Core Evidence 2009:4 61
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Patients with prior coronary artery bypass grafts (CABG) 
have a worse prognosis than those without a history of 
CABG; however, the effect on the incidence of death or 
MI at 30 days with eptifibatide versus placebo was similar 
in patients with prior CABG and in patients without prior 
CABG (14.1% versus 15.5%; unadjusted heart rate 0.89; 95% 
CI 0.80, 0.99).64 In patients with non-ST segment elevation 
ACS who underwent inhospital CABG (n = 1558), eptifiba-
tide treatment resulted in a significantly lower incidence of 
death or MI at 7 days than placebo (17.4% versus 22.3%; 
P = 0.017) that persisted through to the 6-month follow-up 
(27.6% versus 32.7%; P = 0.029).65
Dosage, administration,  
and formulation
Eptifibatide is indicated in the US in patients with UA 
pectoris and NSTEMI. Eptifibatide is indicated for the treat-
ment of patients undergoing PCI, including those undergoing 
intracoronary stenting. It is also indicated for patients with 
angina and NSTEMI that are managed medically. In Europe, 
eptifibatide is indicated for the prevention of early MI in 
patients presenting with UA pectoris or non-Q wave MI 
and with electrocardiogram changes and/or elevated cardiac 
enzymes. Patients at high risk of developing MI within the 
first 3–4 days after onset of acute angina symptoms, including 
those likely to undergo an early percutaneous transluminal 
coronary angioplasty, are recommended for eptifibatide 
therapy.66 Eptifibatide may be administered with heparin 
and aspirin since it was used as a concomitant therapy in 
all the trials.
In adult patients with NSTEMI ACS and normal renal 
function, eptifibatide should be initiated as soon as possible as 
an intravenous bolus of 180 mcg/kg, followed by a continu-
ous infusion (up to 72 hours) of 2.0 mcg/kg/min until hospital 
discharge or the initiation of coronary artery bypass graft 
surgery, up to 72 hours. In those undergoing PCI, the eptifi-
batide infusion should continue until hospital discharge or for 
up to 18–24 hours after the procedure (whichever comes first) 
to a maximum of 96 hours. In patients who are to undergo 
PCI, eptifibatide should be administered as an intravenous 
bolus dose of 180 mcg/kg immediately before the initiation 
of PCI, followed by a continuous infusion of 2.0 mcg/kg/min 
and a second bolus dose of 180 mcg/kg 10 min after the first 
bolus dose. The eptifibatide infusion should continue until 
hospital discharge or for up to 18–24 hours; a minimum of 
12 hours of infusion is recommended.
In patients with renal dysfunction [estimated creatinine 
clearance 3 L/h (50 mL/min)] with non-ST segment 
elevation ACS and/ or undergoing PCI, the dosage of the 
continuous infusion of eptifibatide should be modified 
to 1 mcg/kg/min.
Eptifabatide is contraindicated in patients with a history 
of bleeding diathesis, severe hypertension, major surgery 
within preceding 6 weeks, history of stroke within 30 days 
or any history of hemorrhagic stroke, dependency on renal 
dialysis, or known hypersensitivity to any component of 
the product.
Eptifibatide injection is supplied as a sterile solution in 
10 mL vials containing 20 mg of eptifibatide and 100 mL 
vials containing either 75 mg of eptifibatide or 200 mg of 
eptifibatide. Vials should be stored refrigerated at 2–8 °C 
(36–46 °F).67
Place in therapy
The most significant development in antiplatelet therapy in 
recent years has been the development of the intravenous 
GP IIb/IIIa receptor antagonists (eptifibatide, abciximab, 
tirofiban). These agents act at the final common pathway 
of thrombus formation to prevent the activation of platelets 
and coronary thrombosis. These GP IIb/IIIa agents differ in 
their pharmacologic properties that influence the time course 
and magnitude of platelet inhibition. Abciximab was the 
first of these agents to be developed. Abciximab has limited 
specificity, antigenicity, and a long biological half-life. 
Eptifibatide and tirofiban have greater selectivity, shorter 
half-lives, and limited antigenicity.
GP IIb/IIIa receptor antagonists have been evaluated as 
an adjunctive therapy in patients with ACS. The magnitude 
of the benefit in patients with ACS depends on patient-risk 
stratification, the timing of invasive strategies (including 
PCI), the concurrent use of antithrombotics, dose and choice 
of the GP IIb/IIIa receptor antagonist.68 GP IIb/IIIa receptor 
antagonists are recommended in current treatment guidelines 
of the ACC/AHA.11 In a meta analysis of 31,402 patients with 
ACS who were not scheduled to undergo revascularization,31 
GP IIb/IIIa receptor antagonist treatment was associated with 
a 9% relative risk reduction in the incidence of death or MI 
at 30 days (P = 0.02). This benefit was limited to patients 
with positive troponin levels or who were in need of early 
revascularization. Thus eptifibatide and tirofiban are recom-
mended in conservatively managed patients only if there is 
continuing ischemia, positive cardiac biomarker levels or 
other high-risk factors. None of the GP IIb/IIIa antagonists 
are recommended in the routine management of low-risk, 
troponin-negative patients in whom early angiography is 
not intended.11,12Core Evidence 2009:4 62
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The clinical efficacy of eptifibatide in patients with NSTE 
ACS and/or those undergoing PCI has been determined 
in several large randomized controlled trials (including 
IMPACT-II, ESPRIT, and PURSUIT). In the IMPACT-II 
trial46 the risk reduction provided by eptifibatide (135 mcg/kg 
bolus dose then infusion with 0.5 or 0.75 mcg/kg/min) was 
statistically significant only in the treatment-received 
analysis of the lower dosage. The cause of this unexpected 
outcome was not initially recognized, but subsequent phar-
macodynamic studies indicated that the inhibition of platelet 
aggregation in this study may have been overestimated 
and that a higher eptifibatide dosage was required. Using a 
double-bolus dose of 180 mcg/kg, 10 min apart, with con-
comitant drug infusion of 2.0 mcg/kg/min in patients with 
low-to-moderate risk coronary artery disease undergoing 
elective and urgent PCI with intracoronary stent placement, 
eptifibatide achieved significant reductions in death and 
ischemic complications.44 The ESPRIT researchers con-
cluded that the eptifibatide regimen used in this study was 
better than a strategy of reserving treatment for the bailout 
situation. The dosage regimen used in this trial is now the 
approved dosage regimen for eptifibatide initiated at the 
time of PCI in the US. Retrospective subgroup analyses of 
patients from the PURSUIT trial indicated eptifibatide was 
effective in those who underwent early PCI during the first 
72 hours and that the most favourable 30-day outcomes 
(death or MI) occurred when PCI was conducted within 
24 hours.
The combination of GP IIb/IIIa inhibitors with other 
antiplatelet agents, such as aspirin or clopidogrel, has 
been investigated in low- or intermediate-risk patients 
with coronary artery disease.69,70 The ISAR-REACT70 and 
the ISAR-SWEET (diabetic patients)69 trials evaluated 
the benefits of abciximab in low-risk patients with coro-
nary artery disease undergoing PCI and pretreated with a 
high loading dose of clopidogrel. Overall, there was no 
added benefit from abciximab treatment in these studies. 
In contrast, limited data support regimens that combine 
eptifibatide with other antiplatelet agents such as aspirin 
and clopidogrel (ie, a triple antiplatelet regimen). The role 
of adjunctive GP IIb/IIIa antagonists in patients treated 
with clopidogrel and aspirin requires further investigation, 
especially in regard to patients with different risk profiles 
(eg, high-risk patients who may require more potent anti-
platelet regimens) and in regard to the timing of the dose 
of the thienopyridine.71
The INTERACT study demonstrated that enoxapa-
rin can be substituted for unfractionated heparin in an 
eptifibatide-containing regimen in high-risk patients with 
ACS, including those undergoing PCI. Data investigating 
the efficacy of bivalirudin in patients undergoing PCI 
treated with eptifibatide are limited. The CACHET and 
REPLACE-I and -II trials indicated the efficacy and 
tolerability of bivalirudin in combination with the planned/ 
provisional use of GP IIb/IIIa receptor antagonists (includ-
ing eptifibatide) in patients undergoing PCI.72–74 Large 
comparative clinical trials are still required to definitively 
determine whether bivalirudin is an acceptable substitute 
for unfractionated heparin in combination with the planned 
use of eptifibatide in patients (especially those at high risk) 
undergoing PCI.
Pharmacoeconomic analyses using data from both the 
ESPRIT (patients undergoing PCI) and PURSUIT (patients with 
non-ST segment elevation ACS) trials have demonstrated favor-
able cost-effectiveness ratios for eptifibatide in these indications 
in various countries. Moreover, the PRICE study in patients 
undergoing PCI demonstrated that median total inhospital 
costs were significantly lower in eptifibatide than abciximab 
recipients, with the difference in costs being attributed to higher 
acquisition costs within the abciximab-treated group.
Increased bleeding is a major concern for any agent that 
affects hemostasis. In the large placebo-controlled trials in 
patients with non-ST segment elevation ACS, including those 
undergoing PCI, the beneficial clinical effects of eptifibatide 
were predictably accompanied by an increase in bleeding 
complications, with most major bleeding episodes occur-
ring at the site of vascular access. Major intracranial bleeds, 
stroke, or profound thrombocytopenia rarely occurred during 
eptifibatide treatment. A retrospectivereview of high-risk 
ACS patients treated with eptifibatide, abciximab, or tirofiban 
found that the incidence of bleeding complications did not 
differ significantly among the three agents.75
The efficacy of eptifibatide has been less well investigated 
in patients with STEMI than in those with non-ST segment 
elevation ACS. Preliminary data from the RAPIER study50 
suggests a role for the emergency administration of eptifi-
batide in patients with STEMI before primary angioplasty. 
Currently, several ongoing trials are investigating the role 
of eptifibatide in this setting.
The combination of eptifibatide with a fibrinolytic has 
demonstrated improvements in surrogate markers of reperfu-
sion in patients with STEMI in phase II trials.
Given that the combination of abciximab plus reduced-
dose fibrinolytic was associated with a significantly higher 
incidence of major and minor bleeding than treatment with 
a fibrinolytic [GUSTO-V76 and ASSENT-3,77 studies that are Core Evidence 2009:4 63
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sufficiently powered for tolerability endpoints are required 
before firm conclusions can be drawn regarding the effect of 
a combination of eptifibatide and reduced-dose fibrinolytic 
on the incidence of major hemorrhage. Large random-
ized trials are also needed to establish the tolerability of 
various combinations and dosages of GP IIb/IIIa receptor 
antagonists, fibrinolytics, and antithrombotic agents, with 
careful attention being given to those patients at high risk 
of bleeding.78
To conclude, several large clinical trials provide evi-
dence that intravenous eptifibatide is effective as adjunctive 
therapy to standard therapy in patients with non-ST segment 
elevation ACS, especially in those undergoing PCI. The 
ESPRIT trial demonstrated that in patients undergoing PCI 
with stenting, eptifibatide achieved significant reductions in 
death and ischemic complications compared with placebo. 
Similarly, the PURSUIT trial showed that in patients with 
non-ST segment elevation ACS, eptifibatide was associated 
with a significant reduction in the incidence of death or MI 
compared with placebo. Eptifibatide is well tolerated in these 
indications. Several ongoing trials are currently investigating 
the efficacy and tolerability of eptifibatide along with other 
agents in STEMI and other indications.
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